Pharming Group N.V. (LON:0QCO)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 564.84M -26.2% |
| Revenue (ttm) | 276.22M +7.8% |
| Net Income | 7.01M |
| EPS | 0.01 |
| Shares Out | n/a |
| PE Ratio | 80.57 |
| Forward PE | 37.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 680,305 |
| Open | 0.9263 |
| Previous Close | 0.9126 |
| Day's Range | 0.9065 - 0.9402 |
| 52-Week Range | 0.8339 - 1.8270 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
News
Pharming announces FDA acceptance, Priority review of sNDA for Joenja
Pharming (PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application seeking approval for lower doses of Joenja, an oral, selective phosphoinositide ...
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with AP...
Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
Initial Phase 2 data for Pharming’s (PHAR) Leniolisib in genetically defined PIDs beyond APDS are encouraging, showing improvements in lymphoproliferative measures without new safety signals, with add...
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
Pharming (PHAR) announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies with immune dy...
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report...
Pharming Group Slides: Investor presentation
Pharming Group has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Pharming Gets FDA Approval For Joenja In Children With APDS
(RTTNews) - Pharming Group N.V. (PHARM.AS) said the U.S. Food and Drug Administration has approved Joenja (leniolisib) for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta sy...
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are e...
Pharming Group N.V.: Pharming Group to participate in September investor conferences
Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor ...
Pharming Group to participate in September investor conferences
Pharming Group to participate in investor conferences Sep. 14-15. H.C. Wainwright Growth Conference and Morgan Stanley Healthcare Conference in New York.
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patient...
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V....
Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) investors concerning the Company...
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the Comp...
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and reduced its full-year 2026 outlook by roughly $30 million. Levi & Korsinsky is investigating potenti...
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst c...
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Bost...
Pharming price target raised to $38 from $37 at Canaccord
Canaccord raised the firm’s price target on Pharming (PHAR) to $38 from $37 and keeps a Buy rating on the shares. The firm updated its model following mixed Q2 results…
Pharming Group Slides: Corporate presentation
Pharming Group has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)
Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and PHAR shares fell 22% the day it was reported. Levi & Korsinsky is investigating potential securitie...
Pharming Group Q2 Earnings Call Highlights
Pharming Group NASDAQ: PHAR reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therap...
Pharming Group Earnings Call Transcript: Q2 2026
Revenue guidance for 2026 was lowered, but RUCONEST showed resilience and Joenja delivered 40% year-over-year growth. Operating discipline improved, with strong cash reserves and reduced expense guidance. Near-term catalysts include phase II leniolisib results and global Joenja expansion.
Pharming Group Earnings release: Q2 2026
Pharming Group released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Pharming Group Slides: Q2 2026
Pharming Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.